Market Place
Sourcing Support
Cyclerion’s sGC Stimulator Portfolio Drives Company Growth
17 Dec 2024 //
GLOBENEWSWIRE
Regina Graul, Ph.D., Promoted to Chief Executive Officer
07 Aug 2024 //
GLOBENEWSWIRE
Cyclerion Appoints Regina Graul, Ph.D., as President
04 Dec 2023 //
GLOBENEWSWIRE
Cyclerion Strengthens Board of Directors
30 Nov 2023 //
GLOBENEWSWIRE
Tisento Launches with $81 Million From Promising Cyclerion Assets
31 Jul 2023 //
GLOBENEWSWIRE
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
01 Jun 2023 //
GLOBENEWSWIRE
Cyclerion Announces Reverse Stock Split
15 May 2023 //
GLOBENEWSWIRE
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
11 May 2023 //
GLOBENEWSWIRE
Cyclerion Receives U.S. FDA Orphan Drug Designation for Zagociguat
27 Mar 2023 //
GLOBENEWSWIRE
Hard pressed for cash, Cyclerion looks for help funding rare disease drug
24 Mar 2023 //
ENDPTS
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
22 Mar 2023 //
GLOBENEWSWIRE
Cyclerion Concludes Unsolicited Proposal Is Not in Best Interest of The Company
22 Nov 2022 //
GLOBENEWSWIRE
Cyclerion board quickly nixes CEO Peter Hecht`s unorthodox pitch
22 Nov 2022 //
ENDPTS
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
06 Oct 2022 //
GLOBENEWSWIRE
Cyclerion Announces CY6463 Progress and Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Cyclerion reveals data for schizophrenia therapy
01 Aug 2022 //
PHARMATIMES
Cyclerion Tx Announces Positive Topline Clinical Data for CY6463 in CIAS
28 Jul 2022 //
GLOBENEWSWIRE
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
26 Jul 2022 //
GLOBENEWSWIRE
Cyclerion Tx Provides Additional Positive CY6463 MELAS Clinical Data
28 Jun 2022 //
GLOBENEWSWIRE
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar
22 Jun 2022 //
GLOBENEWSWIRE
Cyclerion Tx Announces CY6463 Data Demonstrating Improved Cellular Energetics
17 Jun 2022 //
GLOBENEWSWIRE
Everest Medicines reaches its first peak in China with Trodelvy nod; & more
11 Jun 2022 //
ENDPTS
Cyclerion Announces Positive Topline Data for CY6463 in MELAS
10 Jun 2022 //
GLOBENEWSWIRE
Cyclerion to Share CY6463 MELAS Topline Study Results
06 Jun 2022 //
GLOBENEWSWIRE
Cyclerion Announces CY6463 Pipeline Progress and Q1 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
24 Feb 2022 //
GLOBENEWSWIRE
Cyclerion Tx, Ariana Pharma Announce AI-driven Precision Medicine Collaboration
23 Feb 2022 //
GLOBENEWSWIRE
Cyclerion Initiates Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease
26 Jan 2022 //
GLOBENEWSWIRE
Cyclerion to Present at Annual Biomarkers for Alzheimer’s Disease Summit
23 Aug 2021 //
GLOBENEWSWIRE
Cyclerion Reports Second Quarter 2021 Financial Results and Corporate Update
29 Jul 2021 //
GLOBENEWSWIRE
Cyclerion to Present CTD CY6463 Phase 2a Study in Participants with Alzheimer
22 Jul 2021 //
GLOBENEWSWIRE
Cyclerion and Beacon Biosignals Announce Expanded Strategic Partnership
09 Jul 2021 //
GLOBENEWSWIRE
Cyclerion & Beacon Biosignals Announce Expanded Strategic Partnership
08 Jul 2021 //
GLOBENEWSWIRE
Cyclerion Therapeutics Announces Publication of CY6463
27 May 2021 //
GLOBENEWSWIRE
Cyclerion Therapeutics to Host Pipeline Update Webinar
20 Apr 2021 //
PRESS RELEASE
Cyclerion fails sickle cell test, prompting pivot to CNS disease
15 Oct 2020 //
FIERCE BIOTECH
Cyclerion axes another program as struggles grow for Peter Hecht`s spinout
14 Oct 2020 //
ENDPTS
Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit
17 Jul 2020 //
GLOBENEWSWIRE
Cyclerion drug`s 4-pronged cracking of neurodegenerative diseases passes early test
22 Jan 2020 //
FIERCE BIOTECH
Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial
31 Oct 2019 //
BIZJOURNALS
